RxDoctor Payments Data

Stella Adu-Gyamfi

Nurse Practitioner · Worcester, MANPI 1033445051

Payments from drug & device makers

$3,023in general payments, 2019–2025

Across 176 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$525
  • AbbVie$412
  • Sunovion Pharmaceuticals Inc.$367
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$357
  • Alkermes, Inc.$354
  • Lundbeck LLC$312
  • plus $696 from 9 others

What the payments were for

  • Food & beverage$2,97698%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,023 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$34,107
Medicare patients
115
Services billed
448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole36$59,102
VraylarCariprazine Hcl24$34,348
Lurasidone Hcl64$33,419
TrintellixVortioxetine Hydrobromide25$13,730
VyvanseLisdexamfetamine Dimesylate31$11,747
Adzenys Xr-OdtAmphetamine11$5,333
Adderall XrDextroamphetamine/Amphetamine18$4,392
Quetiapine Fumarate77$2,890
Bupropion XlBupropion Hcl99$2,116
Olanzapine82$1,405
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine56$1,346
Clonazepam191$1,247
Lamotrigine53$1,100
Trazodone Hcl80$982
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine22$945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$525$59,10236 claims
AbbVieVraylar$412$34,34824 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$78$25,47756 claims
Neos Therapeutics, LPAdzenys Xr-Odt$16$5,33311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →